This is the company's response, as it were. In short, they don't want to go through usual channels, but the ones they've made it through so far are unlikely to yield either robust access or answers. Proof that it's downregulating biomarkers for disease is like saying tissues cure the flu.
They've backtracked, contradicted themselves and embarrassed their co-investigators. The compound's best hope -- and it's unclear whether it deserves one -- is that someone else picks it up or the company is restructured.